Poland

 

Orpea pledges to pay in full as restructuring rumours continue

French elderly care giant Orpea continues to hit the headlines for all the wrong reasons. Over the last week, dozens of facilities were raided by the French authorities, talk continues to be rife about restructuring and potential exits, and contrary to previous assertions HBI understands the group now intends to pay back the full €56m owed to the state.

Scanmed buys Ars Medical

Polish multi-specialty healthcare company Scanmed has bought Polish oncology firm Ars Medical.

Orpea to pay France €25.7m

French multinational care group Orpea has agreed to pay back €25.7m of the €55.8m which the French government says it is owed. The company has also decided to sell €2bn of property.  Its shares continue to bounce around €20-25, down from over €100 pre-scandal.

Affidea deal – underbidders and EBITDA

HBI hears that the surprise buyer of European imaging and cancer treatment provider Affidea, Groupe Bruxelles Lambert (GBL) may not have been the highest bidder, despite winning out. HBI considers who else was in the running, and the EBITDA figure that may have been used for the deal.

Affidea bought by Groupe Bruxelles Lambert

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in European imaging and cancer treatment provider Affidea from B-FLEXION, the private investment firm of the Switzerland-based billionaire Bertarelli family. GBL will invest up to €1bn of equity for the transaction which is its first substantive healthcare investment.

Infermedica targets the USA for expansion

Infermedica, the Polish health tech start-up, will expand its US investments, thanks to the funding gained in a recent Series B financing round. HBI talks with Miłosz Wiciński, Business Development Executive at Infermedica, to learn more.

Will record results for Synlab precipitate Cinven sale?

Almost a year after its IPO, lab giant Synlab has posted strong FY21 results bolstered by Covid, but not, it says, dependant on it. Management say extra cash will be used as a springboard for growth. Could it also lead to private equity majority shareholder Cinven selling its remaining interest?

Find Us